# RenovoRx (RNXT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/RNXT
## Company Profile
- Ticker: RNXT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 1.12 USD
- Market cap: 41062760.5965 USD
- Last updated: 2026-08-12
## Business Overview
### Targeted Intra-Arterial Drug Delivery
RenovoRx develops a localized drug-delivery approach intended to concentrate therapy within solid tumors while reducing systemic exposure. Its Trans-Arterial Micro-Perfusion platform combines a device with a targeted treatment protocol.
### RenovoCath
RenovoCath is an FDA-cleared dual-balloon infusion catheter designed to isolate a vascular segment and deliver therapy through the arterial wall. The device is commercially available to cancer centers as a stand-alone delivery product.
### Broader Solid-Tumor Use
Although RenovoCath was initially used primarily in pancreatic cancer, physicians have begun applying the device in other solid tumors, including sarcoma. This creates a potential route to expand utilization beyond the lead clinical indication.
### TIGeR-PaC
The Phase 3 TIGeR-PaC trial evaluates RenovoCath-mediated intra-arterial gemcitabine in locally advanced pancreatic cancer. Overall survival is the principal registrational objective, and successful results could support a future NDA.
## Why The Stock Is Moving

The latest monitored company update is “RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Completion of the Phase 3 TIGeR-PaC trial in the first half of 2027.
- Topline results from TIGeR-PaC in the second half of 2027.

## Recent News
- 2026-08-12 20:05 EST — [RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth](https://biopharmsignal.com/news/RNXT/renovorx-reports-record-second-quarter-2026-results-driven-by-accelerating-comme-65596425) — Source: RenovoRx
- 2026-08-11 12:30 EST — [RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer](https://biopharmsignal.com/news/RNXT/renovorx-achieves-major-milestone-with-full-enrollment-in-phase-iii-tiger-pac-tr-e7022791) — Source: RenovoRx
- 2026-08-06 12:30 EST — [RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors](https://biopharmsignal.com/news/RNXT/renovorx-announces-first-commercial-clinical-use-of-renovocath-in-sarcoma-patien-e5885230) — Source: RenovoRx
- 2026-08-04 12:30 EST — [RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th](https://biopharmsignal.com/news/RNXT/renovorx-to-highlight-tamp-platform-at-jonestrading-virtual-key-opinion-leader-w-6e36fcef) — Source: RenovoRx
- 2026-07-29 12:30 EST — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) — Source: RenovoRx